Healthcare Professional – AML-ALL Focus EU 2023

You need to register to watch content!

Course Information

Course Instructor

Author

Register now!

FREE

Your personal data will be used to process your registration, support your experience on this website, and for other purposes described in our Privacy Policy.

Opening introduction: Ryan Fitzpatrick, CEO, MD Education

Session I: Fit AML, Chaired by: Charlie Craddock

Research and progress in AML, Hagop Kantarjian – MD Anderson Cancer Center, Houston, Texas

MRD and treatment decision making in Fit AML, Felicitas Thol – Hannover Medical School, Hannover, Germany

Genomics and treatment decision making in Fit adult AML, Paresh Vyas – University of Oxford, UK

Optimising front line management of Fit AML, Alessandro Isidori – Marche Nord Hospital, Pesaro, Italy

Which patients with high-risk AML should we transplant and how?, Charlie Craddock – Queen Elizabeth Hospital, Birmingham, UK

Session 1 Panel Discussion

Session II: Chaired by: Naval Daver

Optimizing frontline therapy for FLT3 mutated AML patients eligible for intensive chemotherapy, Gesine Bug – University Hospital Frankfurt, Germany

Treatment of APML in 2023, Steve Knapper – Cardiff University, UK

Addressing inequity of outcomes and accessing patients with AML, Pramila Krishnamurthy – King’s College Hospital NHS, Foundation Trust

Mechanisms of resistance and novel combinations with venetoclax based therapies in AML, Naval Daver – MD Anderson Cancer Center, Houston, Texas

Session 2 Panel Discussion

Session 2 Independent Discussion supported by Astellas

Session III: Chaired by: Alessandro Isidori

Research and progress in ALLL, Hagop Kantarjian – MD Anderson Cancer Center, Houston, Texas

Novel approaches to treatment of TP53 mutated AML, Emma Searle – Christie Hospital, Manchester, UK

Menin inhibitors, Eunice Wang – Roswell Park Comprehensive Cancer Center, New York, USA

Immunotherapeutic strategies in AML, Sara Ghorashian – University College London

Optimising transplant outcome, Alessandro Rambaldi – University of Milan and Azienda Ospedaliera Papa Giovanni XXIII, Bergamo, Italy

Session 3 Panel Discussion

Session IV: Chaired by: Charlie Craddock & Naval Daver

Yes to Venetoclax, Victoria Potter – King’s College Hospital NHS Foundation Trust, London, UK

Yes to Venetoclax, Alessandro Rambaldi – University of Milan and Azienda Ospedaliera Papa Giovanni XXIII, Bergamo, Italy

No to Venetoclax, Stéphane de Botton, – Tor Vergata University of Rome, Italy

No to Venetoclax, Jurjen Versluis – Erasmus University, Rotterdam

S4 Debate Discussion

Optimal use of Venetoclax in unfit adults in 2023, Jessica Altman – Robert H. Lurie Comprehensive Cancer Center, Chicago, Illinois

Optimal use of Venetoclax in unfit adults in 2023, Priyanka Mehta – University Hospitals Bristol and Weston NHS Foundation Trust, UK

S4 Panel Discussion

Session V: Chaired by: Elias Jabbour & Anna Castleton

Research and progress in ALL, Elias Jabbour – MD Anderson Cancer Center, Houston, Texas

Progress and open questions in treatment of AYA ALL, Christina Peters – St. Anna Children’s Cancer Research Institute, Vienna, Austria

Unmet needs in pediatric ALL, David O’Connor – Great Ormond Street Hospital for Children, UK

MRD in ALL: Clinical Consequences – When and How?, Nicola Gokbuget – University Hospital Frankfurt, Germany

Session 5 Panel Discussion

Session VI: Chaired by: Christina Peters & Cristina Papayannidis

Antibodies in MRD+ ALL, Cristina Papayannidis – Universita di Bologna Italy

Antibodies as “Bridges to SCT” in Ph neg ALL, Sabine Kayser – Medical Faculty Mannheim, Heidelberg University, Germany

How I treat Ph positive ALL in 2023, Elias Jabbour – MD Anderson Cancer Center, Houston, Texas

Session 6 Panel Discussion

Yes for all patients, Phillippe Rousselot – Hôpital de Versailles, France

No for all patients, Sabina Chiaretti – Sapienza University of Rome, Italy

S6 Debate

S6 Independent discussion supported by Jazz

Session VII: Chaired by: Sabina Chiaretti & Elias Jabbour

Optimizing first line therapy in elderly Ph neg B- ALL, Matthias Stelljes – Universitätsklinikum Münster, Germany

Genetics of Ph like ALL, Ilaria Iacobucci – St. Jude Children’s Research Hospital, USA

Treatment strategies for Ph like ALL, Anna Castleton – The Christie NHS Foundation Trust, Manchester, UK

Precision Medicine for T-ALL, Jan Cools – KU Leuven, Belgium, Germany

Session 7 Panel Discussion

Session VIII: Chaired by: Sridhar Chaganti & Cristina Papayannidis

Menin inhibitors in r-KMT2A ALL, Cristina Papayannidis – Universita di Bologna Italy

CAR-T in ALL: present and perspectives, Claire Roddie – University College London, UK

Metabolism and ALL: therapeutic implications, Giovanni Martinelli – IRST IRCCS, Meldola FC, Italy

When not to transplant in newly diagnosed ALL, Sridhar Chaganti – Queen Elizabeth Hospital Birmingham, UK

Session 8 Panel Discussion

AML-ALL EU Focus 2023